Novartis DRC A one-year, single-arm, open-label, multicenter study assessing the effect of brolucizumab on disease control in adult patients with suboptimal anatomically controlled neovascular age-related macular degeneration (SWIFT)
Research Grant
Administered By
Ophthalmology
Awarded By
Novartis Pharma AG
Start Date
August 20, 2020
End Date
September 30, 2023
Administered By
Ophthalmology
Awarded By
Novartis Pharma AG
Start Date
August 20, 2020
End Date
September 30, 2023